Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy
Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy. Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment